These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 20550052

  • 1. Impact of 17P usage on NICU admissions in a managed medicaid population--a five-year review.
    Mason MV, Poole-Yaeger A, Krueger CR, House KM, Lucas B.
    Manag Care; 2010 Feb; 19(2):46-52. PubMed ID: 20550052
    [Abstract] [Full Text] [Related]

  • 2. 17 alpha-hydroxyprogesterone caproate (17P) usage in a Medicaid managed care plan and reduction in neonatal intensive care unit days.
    Mason MV, House KM, Fuest CM, Fitzgerald DR, Kitson BJ, Inglis JA.
    Manag Care; 2005 Oct; 14(10):58-63. PubMed ID: 16277194
    [Abstract] [Full Text] [Related]

  • 3. Optimizing the use of 17P in pregnant managed Medicaid members.
    Mason MV, House KM, Linehan J, Speers CA, Joseph LM, Littlejohn R.
    Manag Care; 2008 Jan; 17(1):47-52. PubMed ID: 18274315
    [Abstract] [Full Text] [Related]

  • 4. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States.
    Petrini JR, Callaghan WM, Klebanoff M, Green NS, Lackritz EM, Howse JL, Schwarz RH, Damus K.
    Obstet Gynecol; 2005 Feb; 105(2):267-72. PubMed ID: 15684150
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Gestational age at initiation of 17-hydroxyprogesterone caproate (17P) and recurrent preterm delivery.
    González-Quintero VH, Istwan NB, Rhea DJ, Smarkusky L, Hoffman MC, Stanziano GJ.
    J Matern Fetal Neonatal Med; 2007 Mar; 20(3):249-52. PubMed ID: 17437227
    [Abstract] [Full Text] [Related]

  • 7. Increased recurrence of preterm delivery with early cessation of 17-alpha-hydroxyprogesterone caproate.
    Rebarber A, Ferrara LA, Hanley ML, Istwan NB, Rhea DJ, Stanziano GJ, Saltzman DH.
    Am J Obstet Gynecol; 2007 Mar; 196(3):224.e1-4. PubMed ID: 17346529
    [Abstract] [Full Text] [Related]

  • 8. Pregnancy outcomes of women receiving compounded 17 α-hydroxyprogesterone caproate for prophylactic prevention of preterm birth 2004 to 2011.
    Sibai BM, Istwan NB, Palmer B, Stanziano GJ.
    Am J Perinatol; 2012 Sep; 29(8):635-42. PubMed ID: 22576126
    [Abstract] [Full Text] [Related]

  • 9. Clinical characteristics of women prescribed 17 alpha-hydroxyprogesterone caproate in the community setting.
    Rittenberg C, Sullivan S, Istwan N, Rhea D, Stanziano G, Newman R.
    Am J Obstet Gynecol; 2007 Sep; 197(3):262.e1-4. PubMed ID: 17826412
    [Abstract] [Full Text] [Related]

  • 10. The risk for preterm labor in women receiving 17 alpha-hydroxyprogesterone caproate prophylaxis for preterm birth prevention.
    Joy S, Rhea DJ, Istwan NB, Desch CN, Stanziano G.
    Am J Perinatol; 2010 Apr; 27(4):343-8. PubMed ID: 20013580
    [Abstract] [Full Text] [Related]

  • 11. 17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis.
    Odibo AO, Stamilio DM, Macones GA, Polsky D.
    Obstet Gynecol; 2006 Sep; 108(3 Pt 1):492-9. PubMed ID: 16946206
    [Abstract] [Full Text] [Related]

  • 12. Women receiving 17-alpha-hydroxyprogesterone caproate hospitalized for preterm labor at less than 34 weeks benefit from daily perinatal nursing surveillance.
    Rittenberg C, Sullivan S, Istwan N, Rhea D, Stanziano G, Newman R.
    Am J Obstet Gynecol; 2008 Oct; 199(4):389.e1-4. PubMed ID: 18928983
    [Abstract] [Full Text] [Related]

  • 13. The impact of maternal body mass on the effectiveness of 17 alpha-hydroxyprogesterone caproate.
    Ventolini G, Duke J, Po W, Barhan S, Rhea D, Desch C, Istwan N, Stanziano G.
    J Reprod Med; 2008 Sep; 53(9):667-71. PubMed ID: 18839818
    [Abstract] [Full Text] [Related]

  • 14. Influence of gestational age and reason for prior preterm birth on rates of recurrent preterm delivery.
    Gonzalez-Quintero VH, Cordova YC, Istwan NB, Tudela F, Rhea DJ, Romary LM, Marimon A, Desch CN, Stanziano GJ.
    Am J Obstet Gynecol; 2011 Sep; 205(3):275.e1-5. PubMed ID: 22071063
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
    Manuck TA, Esplin MS, Biggio J, Bukowski R, Parry S, Zhang H, Huang H, Varner MW, Andrews W, Saade G, Sadovsky Y, Reddy UM, Ilekis J, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Genomics and Proteomics Network for Preterm Birth Research (GPN-PBR).
    Am J Obstet Gynecol; 2016 Mar; 214(3):376.e1-8. PubMed ID: 26692181
    [Abstract] [Full Text] [Related]

  • 17. South Carolina Partners for Preterm Birth Prevention: a regional perinatal initiative for the reduction of premature birth in a Medicaid population.
    Newman RB, Sullivan SA, Menard MK, Rittenberg CS, Rowland AK, Korte JE, Kirby H.
    Am J Obstet Gynecol; 2008 Oct; 199(4):393.e1-8. PubMed ID: 18928985
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery.
    Spong CY, Meis PJ, Thom EA, Sibai B, Dombrowski MP, Moawad AH, Hauth JC, Iams JD, Varner MW, Caritis SN, O'Sullivan MJ, Miodovnik M, Leveno KJ, Conway D, Wapner RJ, Carpenter M, Mercer B, Ramin SM, Thorp JM, Peaceman AM, Gabbe S, National Institute of Child Health and Human Development Maternal Fetal Medicine Units Network.
    Am J Obstet Gynecol; 2005 Sep; 193(3 Pt 2):1127-31. PubMed ID: 16157124
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.